150 related articles for article (PubMed ID: 29514235)
1. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.
Siika A; McCabe L; Bwakura-Dangarembizi M; Kityo C; Mallewa J; Berkley J; Maitland K; Griffiths A; Baleeta K; Mudzingwa S; Abach J; Nathoo K; Thomason MJ; Prendergast AJ; Walker AS; Gibb DM;
Clin Infect Dis; 2018 Mar; 66(suppl_2):S140-S146. PubMed ID: 29514235
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
Hakim J; Musiime V; Szubert AJ; Mallewa J; Siika A; Agutu C; Walker S; Pett SL; Bwakura-Dangarembizi M; Lugemwa A; Kaunda S; Karoney M; Musoro G; Kabahenda S; Nathoo K; Maitland K; Griffiths A; Thomason MJ; Kityo C; Mugyenyi P; Prendergast AJ; Walker AS; Gibb DM;
N Engl J Med; 2017 Jul; 377(3):233-245. PubMed ID: 28723333
[TBL] [Abstract][Full Text] [Related]
3. Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
Post FA; Szubert AJ; Prendergast AJ; Johnston V; Lyall H; Fitzgerald F; Musiime V; Musoro G; Chepkorir P; Agutu C; Mallewa J; Rajapakse C; Wilkes H; Hakim J; Mugyenyi P; Walker AS; Gibb DM; Pett SL;
Clin Infect Dis; 2018 Mar; 66(suppl_2):S132-S139. PubMed ID: 29514234
[TBL] [Abstract][Full Text] [Related]
4. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.
Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C; Melly B; Mudzingwa S; Kelly C; Agutu C; Wilkes H; Nkomani S; Musiime V; Lugemwa A; Pett SL; Bwakura-Dangarembizi M; Prendergast AJ; Gibb DM; Walker AS; Berkley JA;
Lancet HIV; 2018 May; 5(5):e231-e240. PubMed ID: 29653915
[TBL] [Abstract][Full Text] [Related]
5. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
[TBL] [Abstract][Full Text] [Related]
6. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
Lawn SD; Myer L; Bekker LG; Wood R
BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
[TBL] [Abstract][Full Text] [Related]
7. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
8. Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa.
Fatti G; Grimwood A; Nachega JB; Nelson JA; LaSorda K; van Zyl G; Grobbelaar N; Ayles H; Hayes R; Beyers N; Fidler S; Bock P
Clin Infect Dis; 2020 Jan; 70(3):395-403. PubMed ID: 30877753
[TBL] [Abstract][Full Text] [Related]
9. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
10. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.
Li Y; Liu H; Zhang S; Zhang Y; Wang H; Zhang H; Li X
BMC Infect Dis; 2024 May; 24(1):514. PubMed ID: 38778273
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.
Komati S; Shaw PA; Stubbs N; Mathibedi MJ; Malan L; Sangweni P; Metcalf JA; Masur H; Hassim S
AIDS; 2010 Jul; 24(12):1849-55. PubMed ID: 20622529
[TBL] [Abstract][Full Text] [Related]
13. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.
Marcy O; Laureillard D; Madec Y; Chan S; Mayaud C; Borand L; Prak N; Kim C; Lak KK; Hak C; Dim B; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
Clin Infect Dis; 2014 Aug; 59(3):435-45. PubMed ID: 24759827
[TBL] [Abstract][Full Text] [Related]
14. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.
Fenner L; Brinkhof MW; Keiser O; Weigel R; Cornell M; Moultrie H; Prozesky H; Technau K; Eley B; Vaz P; Pascoe M; Giddy J; Van Cutsem G; Wood R; Egger M; Davies MA;
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):524-32. PubMed ID: 20588185
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
[TBL] [Abstract][Full Text] [Related]
16. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
[TBL] [Abstract][Full Text] [Related]
17. Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda.
Masiira B; Baisley K; Mayanja BN; Kazooba P; Maher D; Kaleebu P
Glob Health Action; 2014; 7():21843. PubMed ID: 24433941
[TBL] [Abstract][Full Text] [Related]
18. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality.
Brinkhof MW; Boulle A; Weigel R; Messou E; Mathers C; Orrell C; Dabis F; Pascoe M; Egger M;
PLoS Med; 2009 Apr; 6(4):e1000066. PubMed ID: 19399157
[TBL] [Abstract][Full Text] [Related]
19. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
Madec Y; Laureillard D; Pinoges L; Fernandez M; Prak N; Ngeth C; Moeung S; Song S; Balkan S; Ferradini L; Quillet C; Fontanet A
AIDS; 2007 Jan; 21(3):351-9. PubMed ID: 17255742
[TBL] [Abstract][Full Text] [Related]
20. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
Picat MQ; Lewis J; Musiime V; Prendergast A; Nathoo K; Kekitiinwa A; Nahirya Ntege P; Gibb DM; Thiebaut R; Walker AS; Klein N; Callard R;
PLoS Med; 2013 Oct; 10(10):e1001542. PubMed ID: 24204216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
